Lipocine
LPCN
18 hedge funds and large institutions have $2.46M invested in Lipocine in 2024 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 6 reducing their positions, and 3 closing their positions.
83% more capital invested
Capital invested by funds: $1.35M → $2.46M (+$1.12M)
0.2% less ownership
Funds ownership: 9.11% → 8.91% (-0.2%)
5% less funds holding
Funds holding: 19 → 18 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
33% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 6
Top Buyers
Top Sellers
| 1 |
WE
Wealth Effects
Boston,
Massachusetts
|
-$40.8K |
| 2 |
Morgan Stanley
New York
|
-$2.81K |
| 3 |
Two Sigma Advisers
New York
|
-$1.95K |
| 4 |
BlackRock
New York
|
-$1.26K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$871 |
LPCN Hedge Fund Activity: Q1 2024 in Review
18 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Lipocine (LPCN) for Q1 2024, worth a combined $2.46M — up 83% from $1.35M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of LPCN and 2 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 4 added.
The largest buyer was Susquehanna International Group, adding an estimated $11.9K. The largest seller was Wealth Effects, exiting entirely with an estimated $40.8K sold.
- 18 institutional investors held Lipocine (LPCN) as of Q1 2024, down from 19 in Q4 2023.
- Funds reported $2.46M of Lipocine stock for Q1 2024, up 83% quarter-over-quarter.
- 2 funds opened new Lipocine positions in Q1 2024 and 3 closed out, a net change of -1 holder.
- The largest Lipocine buyer in Q1 2024 was Susquehanna International Group, an estimated $11.9K added.
- The largest Lipocine seller in Q1 2024 was Wealth Effects, an estimated $40.8K sold.
Based on aggregated 13F filings for Q1 2024.